Healthcare giant Johnson & Johnson’s (JNJ) third-quarter earnings results are due on Tuesday before the bell. While the constant threat from biosimilars looms over the company, Johnson and Johnson will … Continue reading Biosimilars might haunt Johnson & Johnson in Q3 as well